Dr. Clay Siegall And Seattle Genetics: Leaders In Innovative Cancer Research

Dr. Clay Siegall is on a mission to transform cancer therapy. He has spent decades doing cancer research and seeking innovative new forms of cancer treatment. Since 2002 Dr. Siegall has been the CEO of Seattle Genetics, a company he co-founded in 1998. The staff is passionate about cancer research and has made major advancements in cancer care. The value of the company’s stock has tripled over the past years due to the ground-breaking new cancer therapies the staff has created. They have helped to dramatically improve the lives of countless cancer patients worldwide.

The key to the success Seattle Genetics has enjoyed is a direct result of the commitment of Dr. Siegall and his staff to serious research, careful implementation of the cutting-edge developments they make and a desire to alleviate the suffering of cancer patients. Under the leadership of Dr. Siegall Seattle Genetics has developed the first effective antibody-drug conjugates including the FDA approved ADCETRIS. The drug has already been used to help cancer patients in 60 countries since its introduction in 2011.

A graduate of George Washington University where he earned a Ph.D. in genetics, Dr. Siegall worked with several internationally-known and respected companies involved in cancer research before founding Seattle Genetics. They include Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Dr. Siegall is also on the boards of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical and the Washington Roundtable. He has also published over 70 scientific articles and holds 15 patents.

Dr. Siegall brings more than just visionary leadership and scientific acumen to Seattle Genetics. He’s also its chief fundraiser and has attracted public and private funding for the company in excess of $1.2 billion. With Dr. Siegall’s guidance Seattle Genetics has multiple strategic licenses for their ADC technology. They include deals with AbbVie, Genentech (Roche), Pfizer and GlaxoSmithKline. Those licenses have generated over $350 million. The company’s internal and collaborator programs have over 20 ADCs in clinical development with Seattle Genetics technology

He has also been given numerous awards and accolades. They include being named 2012 Entrepreneur of the Year by Ernst & Young.

Leave a Reply

Your email address will not be published. Required fields are marked *